Comparative Pharmacology
Head-to-head clinical analysis: LUMENHANCE versus MULTIHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMENHANCE versus MULTIHANCE.
LUMENHANCE vs MULTIHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
Gadobenate dimeglumine is a paramagnetic contrast agent that increases signal intensity in magnetic resonance imaging (MRI) by shortening T1 relaxation times in tissues where it accumulates, primarily due its gadolinium content.
1 mg intravenously once daily
0.1 mmol/kg (0.2 mL/kg) IV as a single bolus injection; maximum dose 0.3 mmol/kg (0.6 mL/kg) for CNS imaging.
None Documented
None Documented
Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment.
Terminal elimination half-life: 2.0 hours in patients with normal renal function (creatinine clearance >60 mL/min); prolonged to up to 30 hours in end-stage renal disease
LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes.
Renal: 95-100% (glomerular filtration) within 72 hours; fecal: <0.1%
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent